Document is current

Article History

Received: 6 February 2022

Revised: 27 April 2022

Accepted: 20 May 2022

First Online: 19 June 2022

Declarations

:

: The PROSCIS-B study received funding from the Federal Ministry of Education and Research via the grant Center for Stroke Research Berlin (01 EO 0801). NMDAR1-abs were measured by the EUROIMMUN/W.Stöcker, Lübeck (Germany) free of cost. EUROIMMUN had neither insight nor influence on data collection other than the antibody measurements. PG, LHAB, SH, SKP, HP, TGL and BS report no disclosures related to this work. PSS reports funding from FAZIT-STIFTUNG between March 2018 and March 2020. BT works at the EUROIMMUN laboratory. PUH reports research grants from the German Ministry of Research and Education, German Research Foundation, European Union, Charité, Berlin Chamber of Physicians, German Parkinson Society, University Hospital Würzburg, Robert-Koch-Institute, German Heart Foundation, Federal Joint Committee (G-BA) within the Innovationsfond, Charité–Universitätsmedizin Berlin (within MonDAFIS; supported by an unrestricted research grant to the Charité from Bayer), University Göttingen (within FIND-AF-randomized; supported by an unrestricted research grant to the University Göttingen from Boehringer-Ingelheim), and University Hospital Heidelberg (within RASUNOA-prime; supported by an unrestricted research grant to the University Hospital Heidelberg from Bayer, BMS, Boehringer-Ingelheim, Daiichi Sankyo), all outside of the submitted work. ME reports grant support from Bayer, the German Research Foundation (DFG), the German Federal Ministry of Education and Research (BMBF), the German Center for Neurodegenerative Diseases (DZNE), the German Centre for Cardiovascular Research (DZHK), the European Union, Corona Foundation, and Fondation Leducq; fees paid to the Charité from Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, Amgen, GlaxoSmithKline, Sanofi, Covidien, Ever, Novartis, all outside of the submitted work.

: All patients or their legal guardian gave written informed consent for study participation. PROSCIS-B was approved by the local ethics committee of the Charité–Universitätsmedizin Berlin and the study was conducted in concordance to ethical principles framed by the Declaration of Helsinki.

: P.S. Sperber, T.G. Liman and B. Siegerink take full responsibility for the clinical data, the analyses and interpretation, and the conduct of the research, have full access to all data, and have the right to publish any and all data.

: Conducted by P.S. Sperber, reviewed by P. Gebert.